Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | El-Dirany, R. (Rima) | - |
dc.creator | Fernández-Rubio, C. (Celia) | - |
dc.creator | Peña-Guerrero, J. (José) | - |
dc.creator | Moreno-Amatria, E. (Esther) | - |
dc.creator | Larrea, E. (Esther) | - |
dc.creator | Espuelas, S. (Socorro) | - |
dc.creator | Abdel-Sater, F. (Fadi) | - |
dc.creator | Brandenburg, K. (Klaus) | - |
dc.creator | Martinez-de-Tejada, G. (Guillermo) | - |
dc.creator | Nguewa, P.A. (Paul Alain) | - |
dc.date.accessioned | 2022-12-05T13:14:00Z | - |
dc.date.available | 2022-12-05T13:14:00Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | El-Dirany, R.; Fernández-Rubio, C. (Celia); Peña-Guerrero, J.; et al. "Repurposing the antibacterial agents peptide 19-4LF and peptide 19-2.5 for treatment of cutaneous leishmaniasis". Pharmaceutics. 24 (11), 2022, 2528 | es |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://hdl.handle.net/10171/64799 | - |
dc.description.abstract | The lack of safe and cost-effective treatments against leishmaniasis highlights the urgent need to develop improved leishmanicidal agents. Antimicrobial peptides (AMPs) are an emerging category of therapeutics exerting a wide range of biological activities such as anti-bacterial, anti-fungal, anti-parasitic and anti-tumoral. In the present study, the approach of repurposing AMPs as antileishmanial drugs was applied. The leishmanicidal activity of two synthetic anti-lipopolysaccharide peptides (SALPs), so-called 19-2.5 and 19-4LF was characterized in Leishmania major. In vitro, both peptides were highly active against intracellular Leishmania major in mouse macrophages without exerting toxicity in host cells. Then, q-PCR-based gene profiling, revealed that this activity was related to the downregulation of several genes involved in drug resistance (yip1), virulence (gp63) and parasite proliferation (Cyclin 1 and Cyclin 6). Importantly, the treatment of BALB/c mice with any of the two AMPs caused a significant reduction in L. major infective burden. This effect was associated with an increase in Th1 cytokine levels (IL-12p35, TNF-¿, and iNOS) in the skin lesion and spleen of the L. major infected mice while the Th2-associated genes were downregulated (IL-4 and IL-6). Lastly, we investigated the effect of both peptides in the gene expression profile of the P2X7 purinergic receptor, which has been reported as a therapeutic target in several diseases. The results showed ... | - |
dc.description.sponsorship | This research was funded by the Spanish Ministry of Science and Innovation (PID2020- 112713RB-C21), Fundación La Caixa (LCF/PR/PR13/51080005), Fundación Roviralta and Ubeso | - |
dc.language.iso | en | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | Leishmaniasis | - |
dc.subject | Drug repurposing | - |
dc.subject | Antimicrobial peptides (AMPs) | - |
dc.subject | Peptide 19-2.5 | - |
dc.subject | Peptide 19-4LF | - |
dc.subject | Drug resistance | - |
dc.subject | Proliferation | - |
dc.subject | Cytokines | - |
dc.title | Repurposing the antibacterial agents peptide 19-4LF and peptide 19-2.5 for treatment of cutaneous leishmaniasis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.description.note | This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). | - |
dc.identifier.doi | 10.3390/pharmaceutics14112528 | - |
dadun.citation.number | 11 | - |
dadun.citation.publicationName | Pharmaceutics | - |
dadun.citation.startingPage | 2528 | - |
dadun.citation.volume | 24 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.